92.31
Rhythm Pharmaceuticals Inc stock is traded at $92.31, with a volume of 1.90M.
It is up +7.86% in the last 24 hours and up +6.98% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$85.58
Open:
$93.9
24h Volume:
1.90M
Relative Volume:
2.25
Market Cap:
$6.33B
Revenue:
$189.76M
Net Income/Loss:
$-196.54M
P/E Ratio:
-29.69
EPS:
-3.1087
Net Cash Flow:
$-156.63M
1W Performance:
+9.66%
1M Performance:
+6.98%
6M Performance:
-7.20%
1Y Performance:
+43.32%
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals Inc
|
92.31 | 5.86B | 189.76M | -196.54M | -156.63M | -3.1087 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday - Yahoo Finance
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) grows Q1 2026 revenue but posts larger net loss - Stock Titan
Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth Potential - Yahoo Finance
Does EU IMCIVREE Expansion for Hypothalamic Obesity Change The Bull Case For Rhythm (RYTM)? - Sahm
Stifel raises Rhythm Pharmaceuticals stock price target on launch By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch - Investing.com
Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call - Benzinga
Earnings call transcript: Rhythm Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates - ChartMill
Rhythm Pharmaceuticals (Nasdaq: RYTM) grows IMCIVREE sales and expands approvals - Stock Titan
Rhythm Pharmaceuticals Q1 revenue rises 84% - TradingView
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q1 Revenue $60.1M, Vs. FactSet Est of $55.8M - Moomoo
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
After FDA approval, rare-obesity drug draws 150 start forms in 6 weeks - Stock Titan
How The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE Expansion - Yahoo Finance
Rhythm Pharmaceuticals Q1 2026 earnings preview - MSN
Rhythm Pharmaceuticals (RYTM) Shares New Insights on Pediatric O - GuruFocus
Rhythm Pharmaceuticals earnings in focus after obesity drug wins By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals earnings in focus after obesity drug wins - Investing.com UK
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society - The Manila Times
Rare obesity trial: 44% of treated children reached healthy or overweight - Stock Titan
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society - TradingView
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo
MSN Money - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rhythm Pharmaceuticals Gains on European Approval for Obesity Drug By Investing.com - Investing.com Canada
European Commission approves Imcivree for hypothalamic obesity - Investing.com
European Commission approves Imcivree for hypothalamic obesity By Investing.com - Investing.com India
Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Jennison Associates LLC - MarketBeat
Rhythm Pharmaceuticals Receives EC Authorization for First FDA-Approved Treatment of Acquired Hypothalamic Obesity in Europe - Quiver Quantitative
Europe authorizes first drug for patients with relentless hunger - Stock Titan
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity - ChartMill
MSN - MSN
RYTM Technical Analysis | Trend, Signals & Chart Patterns | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
Vanguard Capital Management (RYTM) files Schedule 13G for 5.02% stake - Stock Titan
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness - Sahm
[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Board elections and Say-on-Pay on deck for Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Rhythm Pharmaceuticals (RYTM) to Release Earnings on Tuesday - MarketBeat
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Rhythm Pharma wins EU backing to expand Imcivree label - MSN
Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook Reveals 60% Potential Upside In Biotech Sector - DirectorsTalk Interviews
Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):